目的 觀察靈澤片聯(lián)合愛普列特治療良性前列腺增生的臨床療效。方法 納入首都醫(yī)科大學附屬北京康復醫(yī)院2020年6月—2022年6月收治的300例良性前列腺增生癥患者，按照隨機數字表法分為對照組和治療組，每組各150例。對照組口服愛普列特片，5 mg/次，2次/d。治療組在對照組基礎上口服靈澤片，4片/次，3次/d。兩組患者連續(xù)治療6周。觀察兩組患者臨床療效，比較治療前后兩組患者國際前列腺癥狀評分（IPSS）、生活質量指數評分（QOL）評分、膀胱殘尿量、最大尿流率、，性激素睪酮（T）、雌二醇（E₂）、黃體生成激素（LH）和卵泡刺激素（LSH）水平。結果 治療后，治療組總有效率明顯高于對照組（96.67%vs 89.33%，P<0.05）。治療后，兩組患者IPS與QOL評分明顯下降（P<0.05），且治療組患者明顯低于對照組（P<0.05）。治療后，兩組患者殘尿量均明顯減少，而最大尿流率均明顯增加（P<0.05），且治療組改善幅度明顯好于對照組（P<0.05）。治療后，兩組T水平明顯增高，而E₂、LH和FSH水平明顯下降（P<0.05），且治療組性激素水平改善幅度明顯好于對照組（P<0.05）。結論 靈澤片聯(lián)合愛普列特能夠提高良性前列腺增生癥的臨床治療效果，改善臨床癥狀及患者生活質量，該機制可能與調控患者性激素水平相關。

Objective To observe the clinical efficacy of Lingze Tablets combined with epristeride in treatment of benign prostatic hyperplasia. Methods Patients (300 cases) with benign prostatic hyperplasia in Beijing Rehabilitation Hospital Affiliated to Capital Medical University from June 2020 to June 2022 were divided into control group and treatment group according to the numerical table method, with 75 cases in each group.. Patients in the control group was po administered with Epristeride Tablets, 5 mg/time, twice daily. Patients in the treatment group were po administered with Lingze Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical evaluation was evaluated, and the IPSS and QOL scores, bladder residual urine volume and maximum urine flow rate, the levels of sex hormone T, E₂, LH and FSH in two groups before and after treatment were compared. Results After treatment, the total clinical effective rate of the treatment group was significantly higher than that of the control group (96.67% vs 89.33%, P < 0.05). After treatment, the scores of IPS and QOL in two groups decreased significantly (P < 0.05), and the scores in the treatment group were significantly lower than that in the control group (P < 0.05). After treatment, the residual urine volume of two groups was significantly decreased, while the maximum urinary flow rate was significantly increased (P < 0.05), and the improvement in the treatment group was significantly better than that in the control group (P < 0.05). After treatment, the level of T was significantly increased, while the levels of E₂, LH and FSH were significantly decreased in two groups (P < 0.05), and the improvement of sex hormone level in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion Lingze Tablets combined with epristeride can improve the clinical treatment effect of benign prostatic hyperplasia, improve clinical symptoms and patients' quality of life, and this mechanism may be related to the regulation of patients' sex hormone levels.

R983